Abstract
Efforts to cure single gene disorders by replacing the responsible genes using stem cell transplantation and gene transfer have been pursued for decades. These approaches, however, have been confined to serious diseases due in large part to their toxicity. Somatic gene editing (SGE), which repairs undesirable variants, is changing the landscape. It may well have fewer side effects than prior technologies. Thus, it is possible to consider using this approach to address a much broader array of a single gene variants, including treating milder genetic disorders and even improving function in otherwise healthy people. With these possibilities in mind, we discuss three implications of SGE. The first is the complexity of distinguishing between therapy and enhancement as well as the multifaceted debate about the acceptability of the latter, noting that many in the public are opposed to what they see as unfair advantage. The second, which previously has received little attention, is the tremendous price that is likely to be charged for SGE, which makes the debate about enhancement almost moot because even the needs of the most seriously ill will almost surely not be met, raising serious concerns about equity. The last is ensuring adequate regulation and governance of somatic gene editing.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chapman, R. H., Kumar, V. M., Whittington, M. D., & Pearson, S. D. (2021). Does cost-effectiveness analysis overvalue potential cures? Exploring alternative methods for applying a “shared savings” approach to cost offsets. Value in Health, 24(6), 839–845.
Cring, M. R., & Sheffield, V. C. (2020). Gene therapy and gene correction: Targets, progress, and challenges for treating human diseases. Gene Therapy., 29, 3–12.
de la Fuente, J., Gluckman, E., Makani, J., Telfer, P., Faulkner, L., Corbacioglu, S., et al. (2020). The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. The Lancet Haematology, 7(12), e902–e911.
De La Morena, M. T., & Gatti, R. A. (2011). A history of bone marrow transplantation. Hematology/Oncology Clinics, 25(1), 1–15.
Delhove, J., Osenk, I., Prichard, I., & Donnelley, M. (2019). Public acceptability of gene therapy and gene editing for human use: A systematic review. Human Gene Therapy, 31(1–2), 20–46.
Evans, J. H. (2020). The human gene editing debate. Oxford University Press.
Evans, J. H. (2021). Setting ethical limits on human gene editing after the fall of the somatic/germline barrier. Proceedings of the National Academy of Sciences, 118(22).
Fox, T. A., & Booth, C. (2021). Gene therapy for primary immunodeficiencies. British Journal of Haematology, 193(6), 1044–1059.
Gelsinger, P., & Shamoo, A. E. (2008). Eight years after Jesse’s death, are human research subjects any safer? The Hastings Center Report, 38(2), 25–27.
Gostin, L. O., Altevogt, B. M., & Lenzi, R. N. (2014). Oversight and review of clinical gene transfer protocols: Assessing the role of the recombinant DNA advisory committee.
Howell, E. L., Yang, S., Beets, B., Brossard, D., Scheufele, D. A., & Xenos, M. A. (2020). What do we (not) know about global views of human gene editing? Insights and blind spots in the CRISPR era. The CRISPR Journal, 3(3), 148–155.
Irvine, A. (2019). Paying for CRISPR cures: The economics of genetic therapies.
Jasanoff, S., Hurlbut, J. B., & Saha, K. (2019). Democratic governance of human germline genome editing. The CRISPR Journal, 2(5), 266–271.
Jones, R. J., & DeBaun, M. R. (2021). Leukemia after gene therapy for sickle cell disease: Insertional mutagenesis, busulfan, both or neither. Blood, 138, 942–947.
Juengst, E. T. (2020). Annotating the moral map of enhancement: Gene doping, the limits of medicine, and the spirit of sport. In The ethics of sports technologies and human enhancement (pp. 173-202). Routledge.
Juengst, E. T., Henderson, G. E., Walker, R. L., Conley, J. M., MacKay, D., Meagher, K. M., et al. (2018). Is enhancement the Price of prevention in human gene editing? The CRISPR Journal, 1(6), 351–354.
Kaiser, J. (2021). Gene therapy that once led to tragedy scores success. Science, 372(6544), 776.
Krishnamurti, L. (2021). Hematopoietic cell transplantation for sickle cell disease. Frontiers in Pediatrics, 8(846).
Marchant, G. E. (2021). Global governance of human genome editing: What are the rules? Annual Review of Genomics and Human Genetics, 22, 385–405.
Marwick, C. (2003). FDA halts gene therapy trials after leukaemia case in France. BMJ: British Medical Journal, 326(7382), 181–1181.
MedlinePlus. (2021). FGFR3. Retrieved from https://medlineplus.gov/genetics/gene/fgfr3/
Mehlman, M. J. (2018). How will we regulate genetic enhancement? In Rights and resources (pp. 249–281). Routledge.
Murray, T. H. (2018). Good sport: Why games matter and how doping undermines them. Oxford University Press.
National Academies of Sciences, Engineering, & Medicine. (2017). Human genome editing: Science, ethics, and governance. National Academies Press.
National Academies of Sciences, Engineering, & Medicine. (2020). Heritable human genome editing. National Academies Press.
Regulation for the Protection of Human Reseach Participants, Additional protections for research with children, 45 CFR 46, Subpart D, (2021).
Riggan, K. A., Sharp, R. R., & Allyse, M. (2019). Where will we draw the line? Public opinions of human gene editing. Qualitative Health Research, 29(12), 1823–1835.
Saha, K., Sontheimer, E. J., Brooks, P. J., Dwinell, M. R., Gersbach, C. A., Liu, D. R., et al. (2021). The NIH somatic cell genome editing program. Nature, 592(7853), 195–204.
Savulescu, J. (2009). Genetic interventions and the ethics of enhancement of human beings. Readings in the Philosophy of Technology, 417–430.
Scheufele, D. A., Xenos, M. A., Howell, E. L., Rose, K. M., Brossard, D., & Hardy, B. W. (2017). US attitudes on human genome editing. Science, 357(6351), 553–554.
Wilson, R. F. (2010). The death of Jesse Gelsinger: New evidence of the influence of money and prestige in human research. American Journal of Law & Medicine, 36(2–3), 295–325.
World Health Organization. (2023). Sickle Cell Disease. Retrieved from https://www.afro.who.int/health-topics/sickle-cell-disease
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Clayton, E.W. (2023). Therapeutic Genome Editing. In: Valdés, E., Lecaros, J.A. (eds) Handbook of Bioethical Decisions. Volume I. Collaborative Bioethics, vol 2. Springer, Cham. https://doi.org/10.1007/978-3-031-29451-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-031-29451-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-29450-1
Online ISBN: 978-3-031-29451-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)